2nd Workshop European Network on Viral Vaccine Processes

Programme

 

 Monday, October 10, 2011
 09:00 - 09:15 Welcoming remarks and opening of the workshop
L. van der Pol, National Institute for Public Health and the Environment (RIVM), Bilthoven/NL
 1. Viral vaccine development for human and veterinary applications
 
Session chairs:


L. van der Pol, National Institute for Public Health and the Environment (RIVM), Bilthoven/NL
U. Reichl, Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg/D

 09:15 - 10:00 How to leverage novel technologies to improve the development and manufacturing processes, and  overcome the complexities of new vaccines
H. Pinton, Sanofi Pasteur, Marcy L'Étoile/F;
R. Labatut, Sanofi Pasteur, Lyon/F
 10:00 - 10:45 Vaccinating animals to protect human health; the            
development of a save and efficacious Rift Valley
Fever Virus (RVFV) vaccin
e
D. Goovaerts, J.T.M. Koumans MSD Animal Health, Boxmeer/NL
 10:45 - 11:15 Coffee break
 11:15 - 11:45 Flu cell culture vaccines: the Novartis experience
H. Lübben, Novartis Vaccines & Diagnostics GmbH,
Marburg/D; P. Dormitzer, Viral Vaccine Research, NVD
Cambridge, MA/USA
 11:45 - 12:15 Survey for the occurrence of infectious bronchitis           
virus strains in chickens and the quick development
and licensing of a live attenuated vaccine against
QX-like infectious bronchitis virus

H.J. Geerligs, G.J. Boelm, C.A.M. Meinders, B.G.E.
Stuurman, J. Symons, Fort Dodge Animal Health, Weesp/NL; J. Tarres, T. Bru, R. Vila, M.J. Mombarg, Fort Dodge Veterinaria S.A., Gerona/E; K. Karaca, Fort Dodge Labs, Fort Dodge, IA/USA; W. Wijmenga, Fort Dodge Animal Health Benelux B.V., Vaals/NL; M. Kumar, Fort Dodge Animal Health Holland, Naarden/NL

 12:15 - 13:15 Lunch
 2. Viral vaccine products and characterization
 
Session chairs:

S. Kochanek, University Hospital Ulm/D
M.J.T. Carrondo,
Instituto de Biologica

Experimental e Technológica (IBET), Oeiras/Portugal

 13:15 - 14:00 Virosomes as delivery system for antigens
J. Graveland-Bikker, Crucell N.V., Leiden/NL
 14:00 - 14:45 A "cool" way to produce alphavirus VLP vaccines
S.W. Metz, F. Feenstra, C. Geertsema, J.M. Vlak,
G.P. Pijlman, Wageningen University/NL
 14:45 - 15:15 Coffee break
 15:15 - 15:45

Development of a vaccine candidate for human use based on Theravecty's lentiviral vector technology: phase I/II clinical trial by In vivo injection of a therapeutic vaccine ThVO1 against HIV/AIDS
M. Rodrigzuez, C. Bauche, Theravectys SAS, Paris/F

 15:45 - 16:15 Exploring novel approaches to produce virus-like particles
F. Fernandes, J. Vidigal, H. Tomás, M.J.T. Carrondo,
A.S. Coroadinha, A.P. Teixeira, P. Alves, IBET/ITQB-UNL,
Oeiras/P
 16:15 - 16:45 Product fingerprinting for comparability and stability studies
C. J. Westdijk, G.-J. Willems, J.-P. Amorij, National Institute for Public Health and the Environment (RIVM), Bilthoven/NL; A. Hawe, Leiden/Amsterdam Center for Drug Research (LACDR), University of Leiden/NL; G. Kersten, National Institute for Public Health and the Environment (RIVM), Bilthoven/NL
 16:45 - 17:00 Automated analysis of microbial and viral titration assays facilitates validation and GLP compliant, high throughput testing

J. Hare, CTL Europe GmbH, Bonn/D; P. Lehmann, Cellular Technology Limited, Shaker Heights, OH/USA

 19:00 Dinner at the "Fleming's"
Hamburger Allee 47-53, 60486 Frankfurt am Main
 
 Tuesday, October 11, 2011
 3. Trends and challenges in USP & DSP
 
Session chairs:

L. van der Pol, National Institute for Public Health and the Environment (RIVM), Bilthoven/NL
U. Reichl, Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg/D


 09:15 - 10:00 Building on the unique biological properties of embryonic stem cells for the industrial manufacture of vaccines
M. Mehtali, Vivalis SA, Nantes/F
 10:00 - 10:45 MDCK cell line with inducible allele B NS1 expression propagates delNS1 influenza virus to high tires

R. van Wielink, Central Veterinary Institute of Wageningen
UR (CVI), Lelystad/NL and Wageningen University/NL; M.M. Harmsen, Central Veterinary Institute of Wageningen UR (CVI), Lelystad/NL; D.E. Martens, Wageningen University/NL; B.P.H. Peeters, Central Veterinary Institute of Wageningen UR (CVI), Lelystad/NL; R.H. Wijffels, Wageningen University/NL; R.J.M. Moormann, Central Veterinary Institute of Wageningen UR(CVI), Lelystad/NL

 10:45 - 11:00 Cultivation of insect cells in fully synthetic media

F. Messi, Cell Culture Technologies, Gravesano/CH;
C. Ries, R. Eibl, Zurich University of Applied Sciences, Waedenswil/CH

 11:00 - 11:30 Coffee break
 11:30 - 12:00 Trypsin supports high-yield influenza vaccine production in MDCK cells by inhibition of the cellular pathogen defense
T. Frensing, C. Seitz,  Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg/D; U. Reichl, University of Magdeburg/D
 12:00 - 12:30

CIM monolithic columns for the downstream processing and in-process control of large biomolecules production
L. Urbas, M. Peterka, B. Lah Jarc, BIA Separations d.o.o.,
Ljubljana/SLO; E. Szolajska, M. Zochowska,
J. Chroboczek, Polish Academy of Sciences, Warsaw/PL;
M. Barut, A. Strancar, BIA Separations d.o.o., Ljubljana/SLO

 12:30 - 13:00 Improvements on peste des petits ruminants vaccine stability during production and storage

A.C. Silva, ITQB-UNL/IBET, Oeiras/P; M.J.T. Carrondo, IBET, Oeiras, Portugal; P.M. Marques, ITQB-UNL/IBET, Oeiras/P

 13:00 - 13:30

Wrap-up and closing remarks
L. van der Pol, National Institute for Public Health and the Environment (RIVM), Bilthoven/NL

 

Jetzt Mitglied werden